| Autor: |
Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, Kartik Jadhav, MD, DM, Arshad Punjani, MD, Harikishan Boorugu, MD, Ajay Reddy Mari, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Indian Heart Journal, Vol 73, Iss 5, Pp 605-611 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
0019-4832 |
| DOI: |
10.1016/j.ihj.2021.07.005 |
| Popis: |
Objectives: We evaluated the efficacy and safety of dapagliflozin, a SGLT2i along with ARNI in refractory HFrEF irrespective of their diabetic status. Methods: We performed a retrospective analysis of 104 symptomatic patients of HFrEF despite of optimal medical management with ARNI between January–June 2020. Despite the optimal GDMT, dapagliflozin, SGLT2i was added inpatients withrefractory heart failure. At 6-months follow-up, the primary outcome was change in left ventricular ejection fraction, and secondary outcomes included changes in NYHA functional class, vital parameters, renal function, potassium levels, and NT-pro BNP levels. Results: The primary outcomeat 6-months follow-up was a mean change in left ventricular ejection fraction (LVEF) +9.00 ± 0.62 (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
